Pancreatic Cancer Clinical Trials & Research at Providence Medical Group

Pancreatic cancer develops in the pancreatic ductal, acinar, and islet cells. Most pancreatic cancers are adenocarcinoma of pancreatic ductal (PDA) origin. Pancreatic cancer accounts for about 3 percent of all cancers in the U.S. Risk factors that can be changed include tobacco use, obesity, and workplace exposure to certain chemicals.

Providence Medical Group is currently enrolling patients for the following pancreatic cancer clinical trial:

A Phase 1b/2, Multicenter, OpenLabel Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Solid Tumors (EMD Serono MS202329-0010 PROCEADE)

Treatment agent: Anti-CEACAM5 Antibody-Drug Conjugate M9140
Physician: Ian Anderson, MD
Study Coordinator: Camille Shaffer // camille.shaffer@stjoe.org // 707-521-3830
Study Resources: Study Details | Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | ClinicalTrials.gov
Sponsor: EMD Serono Research & Development Institute, Inc
Location: Providence Cancer Center, Santa Rosa, CA

A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation (PCRC EA2192 Apollo)

Treatment agent: Olaparib
Physician: Yao Yao Pollock, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | ClinicalTrials.gov
Sponsor: National Cancer Institute (NCI)
Location: Providence Cancer Center, Santa Rosa, CA

Parallel Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib as Maintenance Therapy in Two Cohorts of Metastatic Pancreatic Cancer Patients with DNA Damage Repair Defects (SWOG S2001)

Treatment agent: Olaparib +/- Pembrolizumab
Physician: Yao Yao Pollock, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: https://clinicaltrials.gov/study/NCT04548752
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA

A Phase II Randomized Trial of Postoperative Adjuvant Capecitabine and Temozolimide versus Observation in High-Risk Pancreatic Neuroendocrine Tumors (SWOG S2104)

Treatment agent: Capecitabine and Temozolimide
Physician: Yao Yao Pollock, MD
Study Coordinator: Beatrice Becker // beatrice.becker@providence.org // 707-932-5164
Study Resources: https://www.clinicaltrials.gov/study/NCT05040360
Sponsor: National Cancer Institute (NCI) / SWOG Cancer Research Network
Location: Providence Cancer Center, Santa Rosa, CA

Study to Assess the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Treatment agent: ART0380 + Irinotecan
Physician: Ian Anderson, MD
Study Coordinator: Melissa Ulrich // melissa.ulrich@providence.org // 707-521-3830
Study Resources: Study Details | A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | ClinicalTrials.gov
Sponsor: Artios Pharma Ltd.
Location: Providence Cancer Center, Santa Rosa, CA

A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2 (CLARITY-PanTumour01)

Treatment agent: AZD0901 is a novel antibody-drug conjugate (ADC) targeting Claudin (CLDN) 18.2.
Physician: Ian Anderson, MD
Study Coordinator: Teresa Lund // teresa.lund@stjoe.org // 707-521-3830
Study Resources: Study Details | AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | ClinicalTrials.gov
Sponsor: AstraZeneca
Location: Providence Cancer Center, Santa Rosa, CA